Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Diuguid

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Hospital Medicine|January 16, 2007
Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patientLuci Leykum, Jacqueline Pugh, David Diuguid, et al.
The American Journal of Medicine|December 31, 2008
Worth a second lookDavid Goldberg, Ilan Weisberg, David Diuguid, et al.
Journal of Critical Care|September 14, 2015
Clinically suspected heparin-induced thrombocytopenia during extracorporeal membrane oxygenationDaryl Glick, Amy L Dzierba, Darryl Abrams, et al.
The Annals of Thoracic Surgery|October 9, 2017
Abciximab/Heparin Therapy for Left Ventricular Assist Device Implantation in Patients With Heparin-Induced ThrombocytopeniaChia-Ling Lee, Paolo C Colombo, Andrew Eisenberger, et al.
Blood Advances|June 24, 2022
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patientsAdam Cuker, Eric K Tseng, Holger J Schünemann, et al.
Blood Advances|February 9, 2021
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19Adam Cuker, Eric K Tseng, Robby Nieuwlaat, et al.
Blood Advances|September 2, 2021
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patientsAdam Cuker, Eric K Tseng, Robby Nieuwlaat, et al.
Blood Advances|May 3, 2022
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patientsAdam Cuker, Eric K Tseng, Robby Nieuwlaat, et al.
Blood Advances|October 22, 2024
American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summaryDeborah M Siegal, Eric K Tseng, Holger J Schünemann, et al.
Blood Advances|November 2, 2021
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxisAdam Cuker, Eric K Tseng, Robby Nieuwlaat, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Hospital Medicine|January 16, 2007
Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patientLuci Leykum, Jacqueline Pugh, David Diuguid, et al.
The American Journal of Medicine|December 31, 2008
Worth a second lookDavid Goldberg, Ilan Weisberg, David Diuguid, et al.
Journal of Critical Care|September 14, 2015
Clinically suspected heparin-induced thrombocytopenia during extracorporeal membrane oxygenationDaryl Glick, Amy L Dzierba, Darryl Abrams, et al.
The Annals of Thoracic Surgery|October 9, 2017
Abciximab/Heparin Therapy for Left Ventricular Assist Device Implantation in Patients With Heparin-Induced ThrombocytopeniaChia-Ling Lee, Paolo C Colombo, Andrew Eisenberger, et al.
Blood Advances|June 24, 2022
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patientsAdam Cuker, Eric K Tseng, Holger J Schünemann, et al.
Blood Advances|February 9, 2021
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19Adam Cuker, Eric K Tseng, Robby Nieuwlaat, et al.
Blood Advances|September 2, 2021
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patientsAdam Cuker, Eric K Tseng, Robby Nieuwlaat, et al.
Blood Advances|May 3, 2022
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patientsAdam Cuker, Eric K Tseng, Robby Nieuwlaat, et al.
Blood Advances|October 22, 2024
American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summaryDeborah M Siegal, Eric K Tseng, Holger J Schünemann, et al.
Blood Advances|November 2, 2021
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxisAdam Cuker, Eric K Tseng, Robby Nieuwlaat, et al.
Pageof 1